Back to Search Results
Study Complete
Sponsor ID
20200199

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Sponsor ID
20200199
Clinicaltrials.gov ID
NCT05599828
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either

famotidine or omeprazole in healthy participants under fed conditions.

Additional Study Details

Phase
Phase 1
Product
AMG 510
Type
Interventional
Masking
None (Open Label)
Enrollment
14
Additional Study Details

Protocol Summary

Primary Outcome Measures

Maximum Observed Plasma Concentration (Cmax) of AMG 510

Timeframe: Day 1, Day 4, Day 11

Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510

Timeframe: Day 1, Day 4, Day 11

AUC from time Zero to Infinity (AUCinf) of AMG 510

Timeframe: Day 1, Day 4, Day 11

Secondary Outcome Measures

Number of Participants with an Adverse Event (AE)

Timeframe: Day 1 to Day 13

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

Location
Status
Contact Us
Location
Covance Clinical Research Unit, Inc
Dallas, TX, United States, 75247
Status
Completed
Study Info
Age
18 - 60 Years
Condition
  • Healthy Subjects
    • Sex
    All
    Trial Dates
    Jul 2020 - Sep 2020
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Healthy male subjects or female subjects, between 18 and 60 years of age (inclusive), at the time of Screening. - Body mass index, between 18 and 30 kg/m2 (inclusive), at the time of Screening. -Females of nonchildbearing potential
    Exclusion Criteria:
    - Inability to swallow oral medication or history of malabsorption syndrome. - History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor. - Poor peripheral venous access. - History or evidence, at Screening or Check in, of clinically significant disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.